Clinical trials: Degenerative Conditions, Neurologic
Parkinson's Disease
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.
- Trial name
- NCT05523570
- Testing
- HNC364
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Early Stage Parkinson Disease
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD.
- Trial name
- NCT00335166
- Testing
- Pardaprunox, pramipexole
- Where
- 89 sites in United States, Australia and 16 more
- Volunteers
- 330 people
- Sponsor
- Solvay Pharmaceuticals
Multiple Sclerosis, Radiologically Isolated Syndrome
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
The goal of the PROCLAIM study is to assess the effectiveness of quantitative brain MRI, as measured by icobrain mr, on the detection of disease activity in multiple sclerosis, including the identification of smouldering disease…
- Conditions
- Multiple Sclerosis, Radiologically Isolated Syndrome, Clinically Isolated Syndrome
- Trial name
- PROCLAIM (NCT07032246)
- Testing
- quantitative brain MRI (icobrain mr), Standard of Care (SOC)
- Where
- 6 sites in Czechia, Germany and 1 more
- Volunteers
- 750 people
- Sponsor
- icometrix
Alzheimer's Disease
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission…
- Trial name
- SUMMIT AD (NCT01254773)
- Testing
- Experimental Bapineuzumab
- Where
- 28 sites in United States
- Volunteers
- 146 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer Disease
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease
Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment for Alzheimer's disease (AD).
- Trial name
- NCT04228666
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences LLC
Age-Related Macular Degeneration
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy…
- Trial name
- NCT05230537
- Testing
- Iptacopan (LNP023)
- Where
- 28 sites in United States, China and 2 more
- Volunteers
- 168 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil
This study is intended to determine the safety and tolerability of ASP0777 in subjects with Alzheimer's Disease (AD) taking a stable dose of donepezil.
- Trial name
- NCT01406145
- Testing
- ASP0777
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Lewy Body Dementia, Non-DLB Dementia
Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical…
- Conditions
- Lewy Body Dementia, Non-DLB Dementia, Alzheimer's, Vascular Dementia
- Trial name
- NCT00209456
- Testing
- DatSCAN
- Where
- Germany
- Volunteers
- 326 people
- Sponsor
- GE Healthcare
Alzheimer's Disease
Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
This is a single centre, 2 part study in older subjects. Part 1 (Pharmacokinetic [PK] Assessment) is a double blind, randomized, placebo-controlled 4-period crossover study investigating the PK profile of four different doses of…
- Trial name
- NCT01702480
- Testing
- GSK2981710
- Where
- United Kingdom
- Volunteers
- 116 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease
Study of ASN51 in Adults With Early Alzheimer's Disease
The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of…
- Trial name
- NCT06677203
- Testing
- ASN51
- Where
- 7 sites in United States
- Volunteers
- 123 people
- Sponsor
- Asceneuron S.A.
Parkinson's Disease
Feasibility Study to Evaluate Deep Brain Stimulation (DBS) Settings for the Treatment of Parkinson's Disease
The purpose of this study is to assess the cognitive performance in patients with advanced Parkinson's disease receiving Deep Brain Stimulation (DBS) with settings predetermined clinically to settings derived from a…
- Trial name
- SAGE (NCT01230151)
- Testing
- GUIDE software, Version 0.1, Clinically defined stimulation parameters
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Intelect Medical, Inc.
Symptomatic Neurogenic Orthostatic Hypotension
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH)…
- Trial name
- RESTORE (NCT02586623)
- Testing
- Droxidopa capsules
- Where
- 168 sites in United States
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Healthy, Alzheimer Disease
A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease
The purpose of this study is to investigate changes of cerebral spinal fluid (CSF) proteins over time using continuous CSF sampling for 36 hours in elderly healthy volunteers and volunteers with mild cognitive impairment or…
- Trial name
- NCT01436188
- Testing
- Standard CSR sampling procedure, Alternate frequency CSR sampling procedure, Standard frequent CSR sampling procedure with 800 mg ibuprofen
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Tourette's Disorder
Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01416441
- Testing
- Aripiprazole
- Where
- 80 sites in United States, Bulgaria and 8 more
- Volunteers
- 170 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease, Huntington's Disease
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.
- Trial name
- NCT00931073
- Testing
- Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Frontotemporal Dementia, FTD
A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes
PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment in patients with…
- Conditions
- Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal
- Trial name
- upliFT-D (NCT04747431)
- Testing
- PBFT02
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Passage Bio, Inc.
Amyotrophic Lateral Sclerosis
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system.
- Trial name
- GALS (NCT01854294)
- Testing
- GM604
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
Parkinson's Disease
A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
This is a randomized, double-blind, two treatment, two group, parallel group study. Subjects will be randomized to one of two treatment groups (E2007 or Placebo) in a 3 to 1 ratio and receive treatment for a total of ten weeks…
- Trial name
- NCT00165789
- Testing
- E2007
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eisai Inc.
Parkinson's Disease (PD)
Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
The purpose of this study is to assess the tolerability of BIA 9-1067 after multiple rising dose regimens of BIA 9-1067.
- Trial name
- NCT02071810
- Testing
- BIA 9-1067
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer´s Disease
Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
This is a follow-up study to assess safety and clinical activity of continued AFFITOPE® AD02 vaccinations in patients with Alzheimer's disease.
- Trial name
- NCT02008513
- Testing
- AFFITOPE® AD02
- Where
- 27 sites in Austria, Croatia and 4 more
- Volunteers
- 194 people
- Sponsor
- Affiris AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.